Back HCV Treatment

HCV Treatment

IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says

HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

Experts Question Cochrane Review of Hepatitis C DAA Treatment

A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticized by doctors and advocates for its conclusion that there is no evidence that the expensive drugs prolong life or reduce liver-related disease in people who achieve a sustained virological response to treatment -- a cure, in current understanding.

alt

Read more:

IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection

AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality among people with hepatitis C virus (HCV) infection, according to a recent report in Clinical Infectious Diseases.

alt

Read more:

FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C

On August 3 the U.S.Food and Drug Administration(FDA) approved AbbVie's new pangenotypic combination pill for people with hepatitis C virus (HCV) genotypes 1 through 6, to be marketed under the brand name Mavyret. Last week the European Commission gave similar approval for the European Union, where the coformulation will be sold as Maviret.

alt

Read more: